Obtaining RNA from Tissue Samples from Patients with Metastatic Kidney, Bladder, Prostate, or Testicular Cancer Undergoing Surgery or Biopsy to Create Immunotherapies

Inclusion Criteria

• Suspected RCC, in the opinion of the investigator
• Availability of either: * Nephrectomy or other surgically removed tissue (stage I); or, * Metastatic RCC biopsy tissue utilizing needle or core biopsy procedures (stage II)
• Number of biopsy specimens available: subjects who are having a surgical procedure (i.e. metastasectomy, nephrectomy) will have core biopsies obtained from the surgical specimen, per the biospecimen repository and processing core (BRPC) protocol * For stage 1: at least 2 cores must be available for transfer to Argos * For stage 2: >= 5 total biopsy cores must be available, so that at least 4 cores may be transferred to Argos
• Not currently being treated with systemic therapy
• EXPANSION COHORT: suspected bladder, kidney, prostate or testicular cancer, in the opinion of the investigator
• EXPANSION COHORT: availability of surgically removed tissue or biopsy tissue
• EXPANSION COHORT: number of biopsy specimens available: subjects who are having a surgical procedure (i.e. metastasectomy) will have core biopsies obtained from the surgical specimen, per the BRPC protocol; otherwise, metastatic tissue will be obtained utilizing needle or core biopsy procedures; at least 2 cores must be available for transfer to Argos; however, as permitted by tumor sample size and morphology, a minimum of four cores should be collected for transfer to Argos to ensure enough tumor sample for AGS-003 production
• EXPANSION COHORT: not currently being treated with systemic therapy

Exclusion Criteria

• Tumor tissue is committed to other use or inadequate for RNA analysis
• Insufficient tissue is collected in the BRPC